Cytosorbents (CTSO) Free Cash Flow Growth (5y) (2015 - 2026)
Cytosorbents (CTSO) Free Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.64 Bn | 176.34 Bn | 6.27 Bn |
| 2 | Stryker | 129.04 Bn | 126.16 Bn | 3.81 Bn |
| 3 | Medtronic | 109.04 Bn | 99.82 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.54 Bn | 67.08 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.67 Bn | 45.00 Bn | 1.29 Bn |
| 6 | Dexcom | 28.40 Bn | 27.28 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.37 Bn | 26.08 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.92 Bn | 26.34 Bn | - |
| 9 | Koninklijke Philips | 25.48 Bn | 22.36 Bn | 2.07 Bn |
| 10 | Cytosorbents | 22.59 Mn | 17.79 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.81% |
| Dec 31, 2025 | -32.24% |
| Sep 30, 2025 | 5.89% |
| Jun 30, 2025 | -23.15% |
| Mar 31, 2025 | -0.13% |
| Dec 31, 2024 | 12.93% |
| Sep 30, 2024 | 13.29% |
| Jun 30, 2024 | -7.66% |
| Mar 31, 2024 | -1.48% |
| Dec 31, 2023 | -19.22% |
| Sep 30, 2023 | -14.35% |
| Jun 30, 2023 | -14.53% |
| Mar 31, 2023 | -4.90% |
| Dec 31, 2022 | 17.20% |
| Sep 30, 2022 | -37.34% |
| Jun 30, 2022 | -29.92% |
| Mar 31, 2022 | -33.85% |
| Dec 31, 2021 | -53.72% |
| Sep 30, 2021 | -2.92% |
| Jun 30, 2021 | -7.31% |